Far from resolved: Stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity
Open accessAbstract
The aim of the present study was to globally characterize the cancer stroma expression profile of muscle-invasive bladder cancer in different metastatic risk groups and to discuss the decisive role of biological pathway change in cancer heterogeneity. Laser capture microdissection was employed to harvest purified muscle-invasive bladder cancer stromal cells derived from 30 clinical samples deriving from 3 different metastatic risk groups. Isobaric tags for relative and absolute quantitation (iTRAQ) and two-dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) were used to identify the differentially expressed proteins. Subsequently, the differentially expressed proteins were further analyzed by bioinformatics tools. After completing the above tasks, the proteins of interest were further compared with the published litterature. We identified 1,049 differentially expressed proteins by paired comparison (high risk vs. median, low risk and normal groups; median risk vs. low risk and normal groups, low risk vs. normal group; a total of 6 comparisons). A total of 510,549,548 proteins as significantly altered (ratio fold-change≥1.5 or ≤0.667 between the metastatic potential risk group and the normal group) were presented in the low/median/high metastatic risk group, respectively. Pathway analysis revealed that the differentially expressed proteins were mainly located in the Kyoto Encyclopedia of Genes and Genomes pathways, including focal adhesion pathway, systemic lupus erythematosus pathway and ECM-receptor interaction pathway. In addition, several proteins such as EXOC4, MYH10 and MMP-9 may serve as candidate biomarkers of muscle-invasive bladder cancer. Our study confirmed that stromal cells, an important part of the cancer tissue, are pivotal for regulating the heterogeneity of cancer. Common changes in biological pathways determined the malignant phenotype of muscle-invasive bladder cancer, and biomarker discovery should take into account both neoplastic cells and their corresponding stromata.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825 · see citing works
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127 · see citing works
Cancer heterogeneity—a multifaceted view
Melo, F. D. S. E., Vermeulen, L., Fessler, E., & Medema, J. (2013) · EMBO Reports · doi:10.1038/embor.2013.92 · Cited by 264 · see citing works
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles, M. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi310 · Cited by 248 · see citing works
Myosin-10 and actin filaments are essential for mitotic spindle function
Woolner, S., O’Brien, L. L., Wiese, C., & Bement, W. M. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200804062 · Cited by 224 · see citing works
Grb2 signaling in cell motility and cancer
Giubellino, A., Burke, T. R., & Bottaro, D. P. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.8.1021 · Cited by 206 · see citing works
Pasin, E., Josephson, D. Y., Mitra, A. P., Côté, R. J., & Stein, J. P. (2008) · Europe PMC (PubMed Central) · Cited by 204 · see citing works
Guo, C., Liu, S., Wang, J.-S., Sun, M., & Greenaway, F. T. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.12.012 · Cited by 201 · see citing works
Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma
van der Horst, G., Bos, L., & van der Pluijm, G. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0274 · Cited by 162 · see citing works
Macrophage Migration Inhibitory Factor (MIF)
Nishihira, J., Ishibashi, T., Fukushima, T., Sun, B., Sato, Y., & Todo, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03220.x · Cited by 138 · see citing works
Henke, C. A., Roongta, U. V., Mickelson, D. J., Knutson, J. R., & McCarthy, J. B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118702 · Cited by 129 · see citing works
Macrophage Migration Inhibitory Factor Activates Hypoxia-Inducible Factor in a p53-Dependent Manner
Oda, S., Oda, T., Nishi, K., Takabuchi, S., Wakamatsu, T., Tanaka, T., Adachi, T., Fukuda, K., Semenza, G. L., & Hirota, K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002215 · Cited by 129 · see citing works
Jung, H., Seong, H., & Ha, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800050200 · Cited by 107 · see citing works
Development of public toxicogenomics software for microarray data management and analysis
Tong, W., Harris, S., Cao, X. M., Fang, H., Shi, L. M., Sun, H., Fuscoe, J. C., Harris, A. J., Hong, H., Xie, Q., et al. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.12.024 · Cited by 107 · see citing works
Saviozzi, S., Cordero, F., Iacono, M. L., Novello, S., Giorgio, S. S. D., & Calogero, R. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-200 · Cited by 105 · see citing works
Johnson, J. L., Pillai, S., Pernazza, D., Sebti, S. M., Lawrence, N. J., & Chellappan, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2647 · Cited by 94 · see citing works
Mechanotransduction at focal adhesions: from physiology to cancer development
Seong, J., Wang, N., & Wang, Y. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12045 · Cited by 77 · see citing works
Self-citationMisra, U. K., Payne, S., & Pizzo, S. V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129767 · Cited by 73 · see citing works
The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer (Review)
Brunner, A., & Tzankov, A. (2007) · Biomarker Insights · doi:10.4137/bmi.s294 · Cited by 44 · see citing works
Ma, J., Cai, W., Zhang, Y., Huang, C., Zhang, H., Liu, J., Tang, K., Xu, P., Katirai, F., Zhang, J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300171 · Cited by 43 · see citing works
Identification of differentially expressed proteins during human urinary bladder cancer progression
Memon, A. A., Chang, J. W., Oh, B. R., & Yoo, Y. J. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.01.002 · Cited by 42 · see citing works
Ioachim, E. E., Michael, M., Stavropoulos, N. E., Kitsiou, E., Salmas, M., & Malamou‐Mitsi, V. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05357.x · Cited by 42 · see citing works
Yamamoto, S., Tsuda, H., Honda, K., Takano, M., Tamai, S., Imoto, I., Inazawa, J., Yamada, T., & Matsubara, O. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04163.x · Cited by 39 · see citing works
Yamamoto, A., Kasamatsu, A., Ishige, S., Koike, K., Saito, K., Kouzu, Y., Koike, H., Sakamoto, Y., Ogawara, K., Shiiba, M., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1356-2 · Cited by 30 · see citing works
Hasebe, T. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.757305 · Cited by 26 · see citing works
Both Myosin-10 Isoforms Are Required for Radial Neuronal Migration in the Developing Cerebral Cortex
Ju, X., Guo, Y., Wang, N.-N., Huang, Y., Lai, M., Zhai, Y.-H., Guo, Y., Zhang, J.-H., Cao, R., Yu, H., et al. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs407 · Cited by 25 · see citing works
Self-citationde Fata, F. R., Ferruelo, A., Andrés, G., Gimbernat, H., Sánchez‐Chapado, M., & Angulo, J. C. (2013) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2013.05.004 · Cited by 12 · see citing works
Kanoh, Y., Ohtani, H., Egawa, S., Baba, S., & Akahoshi, T. (2012) · PubMed · Cited by 11 · see citing works
Niu, H., Shao, S., Zhang, Z., Wu, S., Cheng, B., Pang, D., Yajun, E., Dong, S., Sun, G., & Chang, J. (2008) · International Urology and Nephrology · doi:10.1007/s11255-008-9470-4 · Cited by 3 · see citing works
Self-citation
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227 · see citing works
Developing proteomic biomarkers for bladder cancer: towards clinical application
Frantzi, M., Latosinska, A., Flühe, L., Hupe, M. C., Critselis, E., Kramer, M. W., Merseburger, A. S., Mischak, H., & Vlahou, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.100 · Cited by 83 · see citing works
A bladder cancer microenvironment simulation system based on a microfluidic co-culture model
Liu, P.-F., Cao, Y.-W., Zhang, S.-D., Zhao, Y., Liu, X.-G., Shi, H.-Q., Hu, K.-Y., Zhu, G.-Q., Ma, B., & Niu, H.-T. (2015) · Oncotarget · doi:10.18632/oncotarget.6070 · Cited by 68 · see citing works
Self-citationCheng, P., Cao, T., Zhao, X., Lu, W., Miao, S., Ning, F., Wang, D., Gao, Y., Wang, L., Pei, G., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.021 · Cited by 47 · see citing works
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
Latosińska, A., Mokou, M., Makridakis, M., Mullen, W., Zoidakis, J., Lygirou, V., Frantzi, M., Katafigiotis, I. S., STRAVODIMOS, K. G., Hupe, M. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17279 · Cited by 36 · see citing works
Liu, L., Chen, C., Liu, P., Li, J., Pang, Z.-J., Zhu, J., Lin, Z., Zhou, H., Xie, Y., Lan, T., et al. (2023) · Advanced Science · doi:10.1002/advs.202203423 · Cited by 29 · see citing works
Self-citationRetractedThe mechanobiome: a goldmine for cancer therapeutics
Parajón, E., Surcel, A., & Robinson, D. N. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00409.2020 · Cited by 18 · see citing works
Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics
Carvalho, L. B., Capelo, J. L., Lodeiro, C., Dhir, R., Pinheiro, L. C., López-Fernández, H., Martins, G., Medeiros, M., Díaz, F., & Santos, H. M. (2023) · Communications Medicine · doi:10.1038/s43856-023-00238-4 · Cited by 6 · see citing works
Davalieva, K., Kiprijanovska, S., Ivanovski, O., Trifunovski, A., Саиди, С., Dimovski, A. J., & Popov, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914938 · Cited by 6 · see citing works
The predictive value of PFKFB3 in bladder cancer prognosis
Qiu, D., Zhao, B., Wang, W., Zheng, G., Wang, Z., Wang, X., Li, Y., Liao, Z., Zhao, Y., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31347 · Cited by 4 · see citing works
Self-citationInvestigation of tumour environments through advancements in microtechnology and nanotechnology
Liu, Z., Fan, Y. L., Cui, M., Wang, X., & Zhao, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117230 · Cited by 3 · see citing works
Self-citationLatosińska, A., Vlahou, A., & Makridakis, M. (2018) · Wiley eBooks · doi:10.1002/9781119183952.ch8
Wang, Y., Zhao, Y., Ren, Z., Chen, Y., Chen, L., & Hu, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0361186
Self-citation
- Authors
- LIU, P.-F., WANG, Y.-H., CAO, Y.-W., JIANG, H.-P., YANG, X.-C., WANG, X.-S., & NIU, H.-T.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2014-07-18
- Volume
- 32
- Issue
- 4
- Pages
- 1489-1496
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W1984969754
- Semantic Scholar
- 3b6f3bbf21af32b760becdc25a7b83acec687bf8
- Cited by
- 13
- References
- 30
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81372752, 81101932, 30901481)
- Wu Jieping Medical Foundation (320.6750)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- muscle-invasive bladder cancer, tumor stroma, tumor heterogeneity, metastatic risk, differentially expressed proteins, focal adhesion pathway, ECM-receptor interaction, MMP-9, MYH10, tumor markers
- MeSH terms
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Chromatography, Liquid, Humans, Muscle, Smooth, Neoplasm Invasiveness, Neoplasm Proteins, Prognosis, Signal Transduction, Stromal Cells, Tandem Mass Spectrometry, Laser Capture Microdissection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
